Zarodex Therapeutics

Zarodex Therapeutics is a UK-based biotechnology company specializing in the development of therapeutics that target Z-DNA and Z-RNA binding proteins. As a spin-out from the University of Oxford, the company focuses on the biological significance of alternative nucleic acid structures in disease. Its lead research efforts center on inhibiting ADAR1 (Adenosine deaminase acting on RNA 1) to stimulate the innate immune system against tumors. Zarodex's approach aims to provide new treatment options for patients with cancer and autoimmune conditions by modulating the Z-nucleic acid sensing pathways. The company is backed by Oxford Science Enterprises and leverages world-class expertise in nucleic acid chemistry and immunology.